ADPT — Adaptive Biotechnologies Cashflow Statement
0.000.00%
Last trade - 00:00- $1.17bn
- $1.08bn
- $178.96m
- 58
- 12
- 100
- 57
Annual cashflow statement for Adaptive Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -146 | -207 | -200 | -225 | -160 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 28.9 | 57.4 | 67 | 92.9 | 62.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -40.8 | -56.8 | -71.5 | -46.2 | -17.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -150 | -193 | -184 | -156 | -95.2 |
| Capital Expenditures | -18.8 | -61.7 | -16.3 | -10.7 | -3.66 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -98.2 | 243 | 19.3 | 140 | 81.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -117 | 181 | 2.9 | 130 | 77.8 |
| Financing Cash Flow Items | -0.321 | 0.429 | 124 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 294 | 27.1 | 132 | 2.25 | 0.241 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.9 | 15.6 | -48.8 | -24.4 | -17.2 |